Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

The “Check Before You Inject” ad goes on to note that some vials of compounded semaglutide “have been found to contain ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Eli Lilly stock rose Thursday despite lighter-than-expected sales of its weight-loss and diabetes drugs Zepbound and Mounjaro.

Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Every year, a new list of players is inducted, and this time, there are 15 finalists left, including former New York Giants quarterback Eli Manning, who is attempting to make it in his first year ...

The 19-year-old phenom, who is set to finally take over as a starter in the 2025 season, said he has been bullied by his famous uncles, Peyton and Eli, and they have even given him wedgies.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks. In a fresh appearance on CNBC’s Squawk on the Street, Jim Cramer cautioned ...

Humatrope (Somatropin): Eli Lilly and Company Humatrope (Somatropin), manufactured by Eli Lilly and Company, is recombinant human growth hormone administered for the treatment of growth hormone ...

Novo Nordisk – A global leader in endocrinology that produces Norditropin, a widely prescribed HGH treatment. Eli Lilly and Company – The maker of Humatrope, a leading HGH product used for both ...